China probes Novo Nordisk

Chinese authorities have visited a site operated by Danish drugmaker Novo Nordisk, the world’s biggest maker of insulin, in the latest sign of a widening investigation into western drugmakers. The firm said it co-operated with the visit, as it revealed a better-than-expected 12 per cent rise in quarterly profits to 8.59bn crowns (£964m) and raised its full-year results forecast for the third time in six months.